Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Human VEGFR2 Monoclonal Antibody

Catalog No.: YR0132

Basic Information

Molecular Weight
150 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC.

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone
Ramucirumab Biosimilar

Isotype
Human IgG1 kappa

Immunogen
Human VEGFR2

RecommendedIsotype Control(s)
In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer
1×PBS pH 6.0

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

Product Information

Production
Purified from cell culture supernatant in an animal-free facility

Purification
Protein A or G purification

Storage
Store at -20℃